MicroSectors FANG and Innovation 3X Leveraged ETN vs uniQure N.V. Ordinary Shares — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $33 (market cap $2.93B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is far larger — about 2× uniQure N.V. Ordinary Shares's market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 20 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| FNGU | QURE | |
|---|---|---|
Market Cap | $2.93B | $1.45B |
Volume | 5,898,696 | 3,323,243 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $70.59 |
52-Week Low | $13.73 | $9.03 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | — | $707.46M |
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3X leveraged ETN tracking major tech stocks, trades at $36.69 with a slight 0.22% daily gain. Technical indicators show a bullish trend with strong moving average support, though RSI levels suggest potential overbought conditions. The ETN provides triple exposure to tech giants like Nvidia and Apple but carries significant volatility risks as highlighted by recent analysis of its 87% decline during previous market downturns.
The outlook remains tied to the performance of underlying tech stocks, offering amplified gains in bullish markets but severe losses during corrections. Key risks include leverage decay, concentration in mega-cap tech, and market volatility. Investors should weigh the potential for high returns against the substantial downside exposure inherent in leveraged products.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →